Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
    • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • ONS Congress Newscast
    View All Topics
    Advocacy
    • Latest Articles
    • Get Involved
    Stories View All
    View All
    ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers
    Nurse well-being
    ONS Members Tell Us About the Inspirational Nurses Who’ve Shaped Their Careers
    November 23, 2023
    Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions
    Oncology nurse education
    Nurse Educator–Led Educational Fairs Help Reduce Hospital-Acquired Conditions
    November 10, 2023
    When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey
    Oncology nurse influence
    When the Nurse Coach Becomes the Client: How I Restored Balance and Set Goals on a Healing Journey
    November 03, 2023
    Filipino American History Month nurse standing next to flag
    Nurse empowerment
    Filipino American History Month Shines Light on the Contributions and Challenges of a Committed Community of Nurses
    October 16, 2023
    Explore Somatic Biomarker Testing Report Component Biomarker Testing
    Clinical practice
    Learn How to Read a Somatic Biomarker Testing Report
    October 06, 2023
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
    • Home

    Author Content

    Oncology Drug Reference Sheet: Mirvetuximab Soravtansine-Gynx
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Mirvetuximab Soravtansine-Gynx

    After a single-arm clinical trial demonstrated an overall response rate of 31.7% in 106 patients with folate receptor (FR) alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, the U.S. Food and Drug Administration granted mirvetuximab soravtansine-gynx (Elahere™) accelerated approval on November 14, 2022.  

    October 24, 2023
    Oncology Drug Reference Sheet: Pemigatinib
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Pemigatinib

    When the U.S. Food and Drug Administration (FDA) granted pemigatinib (Pemazyre®) a new indication in August 2022, it became the first targeted therapy approved for treatment of patients with relapsed or refractory myeloid or lymphoid neoplasms (MLNs) with fibroblast growth factor receptor (FGFR) 1 rearrangement. In 2021, FDA gave pemigatinib accelerated approval for patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or other rearrangement as detected by an FDA-approved test.

    March 28, 2023
    The Case of the Costly PARP Inhibitor
    Ovarian cancer

    The Case of the PARP Inhibitor Adherence Assistance

    Mei is a 67-year-old patient who recently underwent an exploratory laparotomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and tumor debulking. Her surgical specimens were sent for pathology review and germline biomarker testing. Based on the findings, Mei was diagnosed with stage IIIC, high-grade serous epithelial ovarian cancer with a BRCA1 pathogenic germline variant.

    January 12, 2023
    PARP Inhibitors and Ovarian Cancer
    Ovarian cancer

    PARP Inhibitors and Ovarian Cancer

    Before poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors were approved for ovarian cancer, traditional treatment consisted of surgical cytoreduction and platinum-based chemotherapy with a taxane, with or without bevacizumab, depending on stage and type. With the surgery-chemotherapy combination, 70%–75% of patients had recurrence and overall five-year survival rates were 29%, indicating a need for additional therapies.

    November 10, 2022
    Oncology Drug Reference Sheet: Asparaginase Erwinia Chrysanthemi (Recombinant)–Rywn
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Asparaginase Erwinia Chrysanthemi (Recombinant)–Rywn

    After more than 93% of patients maintained nadir serum asparaginase activity in the therapy’s clinical trials, on June 30, 2021, the U.S. Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)–rywn (RylazeTM) for use as a component of a multiagent chemotherapeutic regimen for treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase.

    October 25, 2022
    Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD
    Caregiver support

    Help Caregivers Control the Chronic Stress of Cancer Care and Manage PTSD

    Post-traumatic stress disorder can develop after individuals experience an event that goes beyond their usual stressors, affecting a broad range of people. It is associated with exposure to death or threatened death, including a sudden, catastrophic event due to a medical incident. A cancer diagnosis’s significant psychological stressors can affect not only patients, but their caregivers as well.

    September 15, 2022

    To discuss the information in this article with other oncology nurses, visit the ONS Communities.

    To report a content error, inaccuracy, or typo, email pubONSVoice@ons.org.

    Kimberly Rivera DNP, RN-BC, OCN®, NPD-BC
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • ONS
  • Oncology Nursing Foundation
  • ONCC
    • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲